Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer

TUCSON, Ariz. , June 29, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced the customer publication of a peer reviewed journal article featuring